Psychosis and other psychiatric manifestations of levodopa therapy.
about
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesMianserin treatment of patients with psychosis induced by antiparkinsonian drugsAtypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.Ect in neurological counditions.Maladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology updateThe emerging role of clozapine in the treatment of movement disorders.Neuropsychiatry of the basal ganglia.Levodopa addiction. A case study.Atypical antipsychotics in Parkinson-sensitive populations.Psychiatric side effects of medications prescribed in internal medicine.Psychosis in Parkinson's disease.Psychotic symptoms in Parkinson's disease. From description to etiology.New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Psychiatric aspects in Parkinsonism treated with L-dopa.L-dopa and arousal.Clinical risk-benefit assessment of dopamine agonists.Behavioral complications of drug treatment of Parkinson's disease.Drug-induced mania--causative agents, clinical characteristics and management. A retrospective analysis of the literature.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Exosomes in Parkinson's Disease.Genetic disorders presenting as "schizophrenia". Karl Bonhoeffer's early view of the psychoses in the light of medical genetics.Cognitive and psychopathological change in degenerative disease in the elderly.Clozapine therapy in patients with neurologic illness.Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities. SAGE Study Group.Depression in the elderly. II. Possible drug etiologies; differential diagnostic criteria.Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.Psychiatric complications of drug treatment of Parkinson's disease.Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.Drug-induced nightmares.Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.Clozapine prevents recurrence of psychosis in Parkinson's disease.From the biology of dreaming to the biology of the mind.Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years.Emotional functions in short-term vs. long-term L-Dopa therapy in Parkinsonism.An L-dopa paradox: bipolar behavioral alterations.A preliminary study of selected emotional changes in Parkinsonians on L-dopa therapy.Hallucinations in Parkinson disease: neuropsychological study.Psychiatric aspects of L-dopa therapy of Parkinson's disease.Neuropsychiatric effects of Parkinson's disease treatment
P2860
Q26747508-17B44C46-885D-473D-9965-BD522E658055Q28302616-31C0F035-0D0D-4796-8329-180058A0A614Q33884378-9EE4C5AD-B73D-47A3-8089-513C4AD918A2Q34196001-469008D5-3D9F-44C8-B0D7-AADED8F32964Q34423280-078ABDB2-68D5-4A95-AC0E-4CF361477FF6Q34434857-6866A79E-B517-4788-9C9C-E1CD11FB6DE3Q34489109-CD2FCE01-C14F-47AF-A228-3700C6CFD34DQ34563622-7B445291-0B75-41EF-B60B-CCC9AB81D510Q34851726-BC1C60DE-147E-4920-8912-F037B2AD56F2Q35236318-03CEC639-F14F-40DC-B29C-C311F7ABFA82Q35863404-4874A5B0-E3B6-45B6-8BE3-FADA9C5B5E45Q36184471-156EF85D-03AB-4BE8-803E-E93D37791C52Q37021326-1234FDF1-5387-4E65-9E2C-2FB13398EAF3Q37079436-A9EA197F-7581-4ECF-8A44-E8C7BC9DDCEAQ37098326-EB814720-E550-418A-AA57-A4EA56F82E2EQ37243331-2CE3C990-F988-41AD-B17C-B4675160AE3EQ37771070-FD5E5CFC-32BA-453A-89F7-3BEB8C76A108Q38627219-C479DC7F-DAEC-4C22-9DA7-AFCCD0B5FACAQ38662579-D887D8C6-569B-4ABD-9AF8-3451ED752FDFQ39057306-3585B949-62EF-4ED3-A21A-9E996A11666FQ40163401-2C3312A5-378E-4623-8DDB-468392F1E79AQ40817789-DCCDFAD5-32F8-40C1-A24B-3FE7FC300B59Q41122440-A968AE1D-7AD2-48ED-84B4-047D2E11982DQ44769658-0CD1F0A5-7500-4396-ADE6-5117E630DA37Q45013188-EEEFD81A-80C4-42D2-974A-0C2F316E58FAQ46560199-C1020018-8285-46F6-9F72-1F005D723F43Q48701862-EB3DCC0A-2990-4DF0-BE13-0FEC1F02D5D9Q48768086-9AAD2A74-D4FE-4745-B7F8-E468F8FC3AD1Q48771961-B214ED42-056F-4BE7-B1BE-F3F6279F8616Q48859260-59155732-9031-40C7-B299-2E7433455F45Q48893510-5247BAC7-6CD0-42D6-908F-83E78604AE8BQ49123584-DE02EF84-497A-4D58-A0D4-3E234D523077Q50794319-3F4E02C5-7A15-4DAB-BD1C-89B6884B1B14Q51310529-77A353E3-6E0B-451E-8459-EACD92839995Q51316036-0131161A-EBFB-4575-B2C4-6255491A9756Q51316728-AD53DE9A-A382-4C7E-961F-23F4BC9C371FQ52056531-920B29DF-A941-433D-A520-9F67D2DCDBCBQ52121364-79DFAF2C-8D26-43CB-B955-75449A482EDCQ56774001-94F890D8-5B18-45D9-B1AC-A44E5C505AFF
P2860
Psychosis and other psychiatric manifestations of levodopa therapy.
description
1970 nî lūn-bûn
@nan
1970年の論文
@ja
1970年学术文章
@wuu
1970年学术文章
@zh
1970年学术文章
@zh-cn
1970年学术文章
@zh-hans
1970年学术文章
@zh-my
1970年学术文章
@zh-sg
1970年學術文章
@yue
1970年學術文章
@zh-hant
name
Psychosis and other psychiatric manifestations of levodopa therapy.
@en
Psychosis and other psychiatric manifestations of levodopa therapy.
@nl
type
label
Psychosis and other psychiatric manifestations of levodopa therapy.
@en
Psychosis and other psychiatric manifestations of levodopa therapy.
@nl
prefLabel
Psychosis and other psychiatric manifestations of levodopa therapy.
@en
Psychosis and other psychiatric manifestations of levodopa therapy.
@nl
P1433
P1476
Psychosis and other psychiatric manifestations of levodopa therapy.
@en
P2093
P304
P356
10.1001/ARCHNEUR.1970.00480270003001
P577
1970-09-01T00:00:00Z